Company performance
Add to research
Current Price
as of Mar 12, 2025$15.95
P/E Ratio
N/A
Market Cap
$2.32B
Loading...
Description
Add to research
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
Metrics
Add to research
Overview
- HQSan Francisco, CA
- SectorHealth Technology
- IndustryBiotechnology
- TickerDNLI
- Price$15.95+6.05%
Trading Information
- Market cap$2.32B
- Float86.57%
- Average Daily Volume (1m)1,366,206
- Average Daily Volume (3m)1,126,847
- EPS-$2.57
Company
- RevenueN/A
- Rev growth (1yr)-100.00%
- Net income-$422.77M
- Gross marginN/A
- EBITDA marginN/A
- EBITDA-$494.08M
- EV$2.57B
- EV/RevenueN/A
- P/EN/A
- P/SN/A
- P/B1.85
- Debt/Equity4.42
Documents
Add to research
SEC Filings
Factset Street Account
Factset